POSTERS

The following posters and presentations regarding Emerald Biosciences’ technology and data have been presented at several scientific conferences and meetings

Bioavailability of Δ9- Tetrahydrocannabinol (Δ9- THC) from Different Dosage Forms Containing its Prodrug Δ9- THC-VAL-HS (NB1111)
International Cannabinoid Research Society (ICRS) Symposium 2018   >> VIEW POSTER

 

Intraocular Pressure Lowering Efficacy of Δ9- Tetrahydrocannabinol Prodrug, NB1111, in a Normotensive Rabbit Model
International Cannabinoid Research Society (ICRS) Symposium 2017   >> VIEW POSTER

 

Analogue Derivatization of CBD For Improved Ocular Permeation: In Vitro and In Vivo Evaluation
American Association of Pharmaceutical Scientists (AAPS) 2017   >> VIEW POSTER

 

Intraocular Pressure Lowering Activity of Δ9- Tetrahydrocannabinol in α- Chymotrypsin Induced Glaucoma Model:
Dose-Effect Relationship

American Association of Pharmaceutical Scientists (AAPS) 2014   >> VIEW POSTER

 

Development of Δ9- Tetrahydrocannabinol Prodrug with Improved IOP Lowering Efficacy
American Association of Pharmaceutical Scientists (AAPS) 2014   >> VIEW POSTER


SCIENTIFIC PUBLICATIONS

Emerald Bioscience scientists and researchers from collaborating organizations have published scientific articles regarding our proprietary cannabinoid-based therapies in peer-reviewed journals.

 

Adelli GR, Bhagav P, Taskar P, et al. “Development of a D9 tetrahydrocannabinol amino acid-dicarboxylate prodrug with improved ocular bioavailability”. Invest Ophthalmol Vis Sci. 2017; 58:2167–2179. DOI: 10.1167/iovs.16-20757